New drug combo aims to shrink liver tumors before surgery, hoping to keep cancer away longer
NCT ID NCT06280495
First seen Apr 22, 2026 · Last updated Apr 22, 2026
Summary
This study is for people with colorectal cancer that has spread to the liver and can be removed with surgery. It compares the standard chemotherapy (FOLFOX) against the same chemo plus two newer drugs (Serplulimab and Bevacizumab) given before the operation. The goal is to see if the three-drug combination helps the immune system fight the cancer better, leading to fewer cancer cells left after surgery and a longer time before the cancer returns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.